EU HTA Regulation and Joint Clinical Assessment—Threat or Opportunity?
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
The vision of a unified European HTA is by no means a new endeavor. At its core are the publicly declared ambitions to harmonize assessments of clinical data within the EU and avoid the duplication of efforts. Not surprisingly, these ambitions are publicly announced to be motivating the new 2022 EU HTA regulation. However, industry experts typically see more of a risk for additional bureaucracy resulting in delays, further scrutiny, and one additional EU (clinical) dossier to submit on top of all national HTA dossiers, which could be considered a duplication of effort and therefore counterproductive. Regardless of how the details of the process will be defined and how the entire process will work in practice, we can be sure that EU officials will refer to the EU HTA and Joint Clinical Assessment (JCA) in particular as a learning system. The purpose of this article is to take a closer look at the new EU HTA regulation and analyze threats and opportunities for manufacturers and what the resulting opportunities and threats will be at the affiliate level throughout the EU.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“With only around 100 days to submit a JCA dossier after the PICO scope is confirmed, pharmaceutical developers face significant pressure to meet stringent deadlines, potentially impacting the quality and comprehensiveness of the submissions [8, 10].”
From Automated Mass Extraction of Over 680,000 PICOs from Clinical Study Abstracts Using Generative AI: A Proof-of-Concept Study. (2024) · cites this paper as [8]
In the citing paper
“However, the PICO scoping process for the HTAR introduces significant challenges, as input from all EU member states is required to ensure diverse perspectives are considered [8, 12].”
From Automated Mass Extraction of Over 680,000 PICOs from Clinical Study Abstracts Using Generative AI: A Proof-of-Concept Study. (2024) · cites this paper as [8]
In the citing paper
“The JCA will evaluate the health problem(s) addressed by the technology, its technical characterisation and, most critically, its relative clinical effectiveness and safety, which will be standardised using the population, intervention, comparator and outcome (PICO) framework [8–10].”
From Automated Mass Extraction of Over 680,000 PICOs from Clinical Study Abstracts Using Generative AI: A Proof-of-Concept Study. (2024) · cites this paper as [8]
In the citing paper
“The impending implementation of the European Union (EU) Health Technology Assessment Regulation 2021/2282 (HTAR) in January 2025, for instance, will place high demands on pharmaceutical developers for precise and timely SLRs [8–10].”
From Automated Mass Extraction of Over 680,000 PICOs from Clinical Study Abstracts Using Generative AI: A Proof-of-Concept Study. (2024) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2023, December 16). Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15 December 2021 on Health Technology Assessment and Amending Directive 2011/24/EU. Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32021R2282.
(n.d.)
Unresolved(2023, December 16). EUnetHTA 21, Practical Guideline D4.2 Scoping Process, Version 1.0, Sep 12, 2022 (Template Version Sep 30, 2021). Available online: https://www.eunethta.eu/wp-content/uploads/2022/09/EUnetHTA-21-D4.2-practical-guideline-on-scoping-process-v1.0.pdf.
(n.d.)
Unresolved(2023, December 17). EUnetHTA, D5.1 JCA/CA, Submission Dossier Template, Version 1.0. Available online: https://www.eunethta.eu/wp-content/uploads/2021/12/EUnetHTA-21-D5.1-JCA_CA-Submission-Dossier-Template-Project-Plan-v1.0.pdf.
(n.d.)
Unresolved(2023, December 17). EUnetHTA 21, D5.1, Submission Dossier Guidance, Version 1.0. Available online: https://www.eunethta.eu/wp-content/uploads/2022/12/EUnetHTA-21-D5.1-Submission-Dossier-Guidance-v1.0.pdf.
(n.d.)
Unresolved
Cited by
Reason, T., Langham, J., & Gimblett, A. (2024) · Pharmaceutical Medicine · doi:10.1007/s40290-024-00539-6 · Cited by 16
“They are widely required by national HTA agencies and will be a key component of the EU HTAR JCA process [8–10].”
BackgroundMethodInfluentialReason, T., Wu, Y., Jones, C., Benbow, E., Johannesen, K. M., & Malcolm, B. (2025) · Value in Health · doi:10.1016/j.jval.2025.08.001 · Cited by 7
Performance of the accelerated assessment of the European Medicines Agency
Grosso, V. D., Perini, M., Casilli, G., Costa, E., Boscaro, V., Miglio, G., & Genazzani, A. A. (2025) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16385 · Cited by 6
Julian, E., Belleman, T., Garcia, M. J., Mölken, M. R., Doeswijk, R., Giuliani, R., Wormann, B. J., Widmer, D., Tilleul, P. R., Casado-Arroyo, R., et al. (2025) · Journal of Market Access & Health Policy · doi:10.3390/jmahp13010006 · Cited by 6
“As the JCAs aim to address MS requirements, which will in some cases differ due to national health system contexts, the EU HTA is an opportunity to achieve closer alignment and ultimately an EU Health Union [3,19,29,36].”
van Beekhuizen, S., Che, M., Monfort, L., Hashim, M., Azough, A., Kubitz, N., Griffin, A., & Price, M. (2025) · PharmacoEconomics - Open · doi:10.1007/s41669-025-00575-1 · Cited by 5
“Although EU member states must give the EU JCA ‘due consideration’, national HTA agencies may also conduct complementary clinical assessments (including ITCs) that consider a different PICO and/or methodology [2, 42], ultimately leading to a conclusion that may differ from the EU JCA.”
Metadata
- Authors
- Schuster, V.
- Affiliations
- SAI MedPartners, Reading, PA 19606, USA
- Corresponding author
- Schuster, Volker
- Venue
- Journal of Market Access & Health Policy
- Publisher
- MDPI AG
- Published
- 2024-05-13
- Volume
- 12
- Issue
- 2
- Pages
- 100-104
- ISSN
- 2001-6689 (ISSN-L)
- PMC
- PMC11130920
- OpenAlex
- W4396938377
- Cited by
- 22
- References
- 4
- Citations by year
- 2026: 11 · 2025: 10 · 2024: 1
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Market Access & Health Policy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Regulation
- Keywords
- EU HTA Regulation, Joint Clinical Assessment, pharmaceutical manufacturers, regulatory burden, learning systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EU HTA Regulation and Joint Clinical Assessment—Threat or Opportunity? https://app.cochat.ai/papers/10.3390/jmahp12020008
- The paper
- Schuster, V. (2024). EU HTA Regulation and Joint Clinical Assessment—Threat or Opportunity? Journal of Market Access & Health Policy. https://doi.org/10.3390/jmahp12020008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
